RetaMaps

MD Anderson Endocrine Center — Conor J. Best, MD

MD Anderson Endocrine Center (Main Building) · 1515 Holcombe Blvd · Houston, TX 77030

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

This is the same MD Anderson Endocrine Center / Department of Endocrine Neoplasia and Hormonal Disorders at 1515 Holcombe Blvd in Houston—an academic cancer-center program for thyroid, adrenal, parathyroid, pituitary, and pancreatic neuroendocrine disease plus cancer-related hormonal complications. Conor J. Best, MD, is listed as Associate Professor and Clinical Medical Director of the department. Appointments run through MD Anderson intake; official pages do not name GLP-1 weight-loss brands.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visits—
Cash pay acceptedYes
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Clinicians

  • Conor J. Best, MD

Other locations of this practice

Nearby providers in Houston

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs